3-Bromo-7-nitroindazole

Name: 3-Bromo-7-nitroindazole
Brand: MedChemExpress
SKU: HY-101175
Rating: 4.5 (1 reviews)

Cat. No.: HY-101175 Purity: 99.78%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

3-Bromo-7-nitroindazole is a potent and selective inhibitor of neuronal nitric oxide synthase (nNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain. 3-Bromo-7-nitroindazole can be used for the researches of metabolic and neurological disease, such as diabetes, stroke and depression.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

3-Bromo-7-nitroindazole 화학구조

CAS No. : 74209-34-0

사이즈	재고	수량

무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	해외재고보유	Estimated Time of Arrival: December 31
500 mg	견적 받기
1 g	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE 3-Bromo-7-nitroindazole

•Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NO Synthase Isoform Specific Products:

View All Isoforms

nNOS iNOS eNOS

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target

nNOS

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	80 3 Compound: 12	Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs	[PMID: 18502134]
RAW264.7	IC₅₀	80 3 Compound: 12	Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs	[PMID: 18502134]
RAW264.7	IC₅₀	80 3 Compound: 12	Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs	[PMID: 18502134]

In Vivo

3-Bromo-7-nitroindazole (5-20 mg/kg, i.p., daily for 5 days) impairs spatial learning and memory in rats^[1].
3-Bromo-7-nitroindazole (3-30 mg/kg, i.p.) attenuates brain ischemic injury in diabetic stroke rats^[2].
3-Bromo-7-nitroindazole (20 mg/kg, i.p., daily for 5 weeks) inhibits chronic unpredictable mild stress (CUMS)-induced depression-like behavior in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats^[1]
Dosage:	5, 10 and 20 mg/kg
Administration:	Intraperitoneally injection, daily for 5 days
Result:	Impaired the acquisition of the MWM task. Impaired the probe trial. Decreased the increased brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus. Had no effects on locomotor activity and blood pressure.

Animal Model:	Type 2 diabetic rats induced by feeding high-fat diet and streptozotocin (HY-13753) with MCAO^[2]
Dosage:	3, 10 and 30 mg/kg
Administration:	Intraperitoneally injection
Result:	Inhibited the cerebral infarct, edema volume. Improved functional recovery of neurological deficits. Decreased DNA fragmentation with a concomitant reduction of GRP78 and CHOP.

Animal Model:	Chronic unpredictable mild stress (CUMS)-induced rats models^[3]
Dosage:	20 mg/kg
Administration:	Intraperitoneally injection, daily for 5 weeks
Result:	Reduced sucrose preference, body-weight and locomotor activity. Increased immobility time in the FST. Increased BDNF protein levels in the CA1 and CA3 regions of the hippocampus.

분자량

242.03

화학식

C₇H₄BrN₃O₂

CAS No.

74209-34-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=[N+](C1=CC=CC2=C1NN=C2Br)[O-]

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 100 mg/mL (413.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.1317 mL	20.6584 mL	41.3169 mL
5 mM	0.8263 mL	4.1317 mL	8.2634 mL
10 mM	0.4132 mL	2.0658 mL	4.1317 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.78%

Select Batch:

Data Sheet (282 KB) SDS (396 KB)

COA (255 KB) RP-HPLC (255 KB) MS (83 KB)

Handling Instructions (2659 KB)

References

[1]. Gocmez SS, et al. The effect of a selective neuronal nitric oxide synthase inhibitor 3-bromo 7-nitroindazoleon spatial learning and memory in rats. Pharmacol Biochem Behav. 2015 Apr;131:19-25. [Content Brief]

[2]. Srinivasan K, et al. 3-Bromo-7-nitroindazole attenuates brain ischemic injury in diabetic stroke via inhibition of endoplasmic reticulum stress pathway involving CHOP. Life Sci. 2012 Jan 16;90(3-4):154-60. [Content Brief]

[3]. Yazir Y, et al. Inhibition of neuronal nitric oxide synthase and soluble guanylate cyclase prevents depression-like behaviour in rats exposed to chronic unpredictable mild stress. Basic Clin Pharmacol Toxicol. 2012 Sep;111(3):154-60. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.1317 mL	20.6584 mL	41.3169 mL	103.2921 mL
	5 mM	0.8263 mL	4.1317 mL	8.2634 mL	20.6584 mL
	10 mM	0.4132 mL	2.0658 mL	4.1317 mL	10.3292 mL
	15 mM	0.2754 mL	1.3772 mL	2.7545 mL	6.8861 mL
	20 mM	0.2066 mL	1.0329 mL	2.0658 mL	5.1646 mL
	25 mM	0.1653 mL	0.8263 mL	1.6527 mL	4.1317 mL
	30 mM	0.1377 mL	0.6886 mL	1.3772 mL	3.4431 mL
	40 mM	0.1033 mL	0.5165 mL	1.0329 mL	2.5823 mL
	50 mM	0.0826 mL	0.4132 mL	0.8263 mL	2.0658 mL
	60 mM	0.0689 mL	0.3443 mL	0.6886 mL	1.7215 mL
	80 mM	0.0516 mL	0.2582 mL	0.5165 mL	1.2912 mL
	100 mM	0.0413 mL	0.2066 mL	0.4132 mL	1.0329 mL